Treatment Plan for an Individual Patient With Pasireotide for Hyperinsulinemic Hypoglycemia
Latest Information Update: 04 Oct 2021
Price :
$35 *
At a glance
- Drugs Pasireotide (Primary)
- Indications Hyperinsulinaemia; Hypoglycaemia
- Focus Therapeutic Use
- 27 Sep 2021 Status changed from recruiting to completed.
- 08 Jul 2019 Planned End Date changed from 22 Mar 2019 to 22 Mar 2022.
- 08 Jul 2019 Planned primary completion date changed from 22 Mar 2019 to 22 Mar 2022.